Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:VVOS

Vivos Therapeutics Q3 2026 Earnings Date & Estimates

Vivos Therapeutics logo
$0.10 +0.00 (+2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.10 0.00 (-0.84%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivos Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vivos Therapeutics in Q3 2026

Vivos Therapeutics is expected to post earnings of -$0.30 per share on revenue of $5.48 million. In the same quarter a year earlier Vivos Therapeutics reported -$0.49 per share on revenue of $6.78 million. Vivos Therapeutics last reported on August 14, 2026, posting -$0.31 per share and beating the -$0.41 consensus estimate. Vivos Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.30
Expected Revenue
$5.48 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$6.78 million
Expected Revenue Growth
-19.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.31 (Beat by +$0.10)
Last Quarter Revenue
$5.15 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Vivos Therapeutics Q3 2026 Earnings FAQ

Vivos Therapeutics (NASDAQ:VVOS) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Vivos Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 18, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Vivos Therapeutics to post earnings of -$0.30 per share for Q3 2026.

The consensus revenue estimate for Vivos Therapeutics is $5.48 million for Q3 2026.

Vivos Therapeutics Earnings Headlines

Head to Head Contrast: Intelligent Bio Solutions (NASDAQ:INBS) versus Vivos Therapeutics (NASDAQ:VVOS)
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173411
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/8531730/correction-sod-sciences-welcomes-vivos-therapeutics-as-strategic-investor-and-partner-in-the-rebalu-primed-cell-test/
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
November 9 at 1:00 AM  |  Porter & Company (Ad)
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
October 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vivos-therapeutics-reports-nasdaq-confirmation-of-compliance-with-continued-listing-shareholders-equity-standard-1036648709
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385390/0/en/vivos-therapeutics-reports-nasdaq-confirmation-of-compliance-with-continued-listing-shareholders-equity-standard.html
SOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69886525-sod-sciences-inc-sod-sciences-welcomes-vivos-therapeutics-as-strategic-investor-and-partner-in-the-rebalu-primed-cell-test-200.htm
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies.

The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep. Vivos also provides clinical protocols, practitioner training, patient support, and an integrated practice model intended to help dental professionals identify and treat airway-related disorders.

Vivos Therapeutics was founded in 2016 and is headquartered in Denver, Colorado. The company markets its products primarily through dental and medical professionals in the United States and has also reported pursuing opportunities in international markets. Kirk Huntsman has served as the company’s chief executive officer. Vivos Therapeutics became a publicly traded company on Nasdaq in 2021 under the symbol VVOS.

View Vivos Therapeutics Profile
Earnings Tools